8.22  0 (0%)		04-24 15:47
Open: 8.24 High: 8.25 Volume: 3,151,400		Pre. Close: 8.22 Low: 8.18 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Adamas Pharmaceuticals, Inc. is focused on the research, development, and commercialization of therapeutic solutions for individuals in the United States suffering from chronic neurological conditions. The company's marketed products include GOCOVRI, an extended-release capsule designed to treat dyskinesia in Parkinson's disease patients who are undergoing levodopa-based therapy, with or without other dopaminergic medications. Additionally, they provide Namzaric capsules, a combination of extended-release memantine hydrochloride and donepezil hydrochloride, used for managing moderate to severe Alzheimer's-type dementia. In its development pipeline, Adamas is progressing ADS-5102, which is currently undergoing Phase III clinical trials to address walking difficulties in patients with multiple sclerosis, among other potential applications. The firm has also completed two Phase I studies for ADS-4101, a candidate treatment for partial onset seizures in epilepsy patients. Founded in 2000, the company initially operated as NeuroMolecular Pharmaceuticals, Inc. before changing its name to Adamas Pharmaceuticals, Inc. in July 2007. Its corporate headquarters are located in Emeryville, California.

Tue, 01 Nov 2022
David Kroin Net Worth (2026) - GuruFocus

Wed, 07 Sep 2022
John J. Cadeddu Net Worth (2026) - GuruFocus

Wed, 24 Nov 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals - Yahoo Finance

Mon, 11 Oct 2021
Supernus bolsters Parkinson's portfolio with $400 mln deal for Adamas Pharma - Reuters

Fri, 07 Aug 2020
Bulletin Board Heroes, USA Penny Stocks, Friday 7th August 2020 - Share Talk

Wed, 19 Dec 2018
The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date